About this Special Issue
Whilst COVID-19 can be fatal, for the vast majority of healthy people infected with the virus, the condition is a short lived, albeit unpleasant, respiratory infection with no long-lasting symptoms. However, it has become increasingly apparent that approximately 10% of infected individuals experience long term detrimental side effects following infection with the causative SARS-CoV-2 virus, a condition that has been termed, ‘Long COVID’*. Long COVID manifests in a myriad of different conditions and the underlying mechanisms involved in Long COVID, have yet to be elucidated. In this special issue we invite papers that investigate the range of conditions associated with Long COVID, to include but not limited to;
- Coagulation & Hematological
- Respiratory e.g. alveolar fibrosis
- Gastrointestinal & microbiota
* Long COVID can also be referred to as “postacute sequelae of SARS-CoV-2 infection (PASC)” or “long-haul COVID”.
The type of articles submitted can comprise original research, reviews and case studies.
Manuscript Submission Deadline: January 31st 2024
Any questions? Please email the Editorial Office.
IBMS members can benefit from a full waiver of the APC and should email the Editorial Office with their IBMS membership reference number prior to submission of the manuscript to confirm their waiver.
Keywords: COVID-19, infection, OpenAccess, COVID, long COVID, postacute sequelae of SARS-CoV-2 infection (PASC), long-haul COVID disease